Capecitabine Monotherapy as Palliative Treatment for Patients with Recurrent/Metastatic Nasopharyngeal Cancer

Table 5

Summary of capecitabine trials of recurrent/metastatic NPC.

Author, year	Region	Number of patients	Capecitabine protocol	ORR	mPFS	mOS
Chua et al., 2003 [19]	Asia	17	1,250 mg/m^2 BID for 2 weeks, Q3 weeks	23.5	4.9	7.6
Chua et al., 2008 [20]	Asia	49	1,000–1,250 mg/m^2 BID for 2 weeks, Q3 weeks	37	5	14
Ciuleanu et al., 2008 [26]	Europe	23	2,500 mg/m^2 BID for 2 weeks, Q3 weeks, to a maximum of six cycles	48	14	NR^a
Current study, 2022	Middle East	51	1,250 mg/m^2 BID for 2 weeks, Q3 weeks	49	6.6	32.7

^aNot reached at 18 months and 1-year OS was 62%. Abbreviations: BID: twice a day; mOS: median overall survival; mPFS: median progression-free survival; NPC: nasopharyngeal carcinoma; ORR: objective response rate; Q3 weeks: every 3 weeks.